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Objectives. This study was undertaken to examine the influence 
of plasma lipoprotein(a) [Lp(a)] levels on coronary endothelial 
vasomotor function. 
Background. Epidemiologic studies have demonstrated a direct 
relation between elevated plasma levels of Lp(a) and increased 
risk of coronary artery disease. Well recognized coronary risk 
factors are known to affect endothelium-dependent vasomotion; 
however, the influence of Lp(a) on coronary vasomotor function 
has not been determined. 
Methods. We used quantitative coronary angiography to mea- 
sure left anterior descending coronary artery diameter changes 
produced by intracoronary acetylcholine and isosorbide dinitrate 
in 30 patients with angiographically normal coronary arteries. 
Plasma Lp(a) levels were determined with enzyme-linked immu- 
nosorbent assay. 
Results. Vasomotor response to acetylcholine ranged from 
+13% to -47% in the proximal, from +23% to -53% in the 
middle and from +13% to -56% in the distal segment of the left 
anterior descending coronary artery. According to univariate 
linear regression analysis, Lp(a) had a significant inverse corre- 
lation with vasomotor response to acetylcholine: r = 0.47, p < 0.01 
in the proximal; r = -0.61, p < 0.001 in the middle; and r = 
-0.52, p < 0.01 in the distal segment of the left anterior 
descending coronary artery. By multiple stepwise regression anal- 
ysis, plasma Lp(a) was the significant predictor of vasomotion i  
response to acetylcholine in all tested segments (p < 0.01). 
Conclusions. Elevated Lp(a) levels were associated with impair- 
ment of endothelium-dependent vasodilation even when athero- 
sclerotic lesions were not recognizable by angiography. This 
finding suggests that elevated plasma levels of Lp(a) cause 
endothelial dysfunction and may contribute in part to later develop- 
ment of atherosderosis, as shown in epidemiologic studies. 
(J Am CoU Cardio11995;26:1242-50) 
Lipoprotein(a) [Lp(a)] is a cholesterol-rich plasma lipoprotein, 
first described by Berg in 1963 (1). The lipid composition of 
Lp(a) is similar to that of low density lipoprotein (LDL), but 
the major protein components are different, consisting of 
apolipoprotein B-100 and additional specific glycoprotein apo- 
lipoprotein(a) (2). Recent epidemiologic studies have shown a 
direct relation between elevated plasma Lp(a) levels and 
increased prevalence of coronary heart disease (3-8) and 
cerebrovascular disease (8-10). However, the precise patho- 
physiologic mechanism by which elevated Lp(a) levels contrib- 
ute to the development of atherosclerosis remains unclear. 
Endothelial cell injury is an initiating factor in the develop- 
ment of atherosclerotic lesions (11). Endothelial dysfunction 
promotes the development of atherosclerosis in association 
with attenuation of antithrombotic properties (12); activated 
interactions with leukocytes or platelets, or both (13,14); 
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and disorder in vasomotion (15-17). To assess coronary endo- 
thelial function in vivo, analysis of vasomotion i response to 
intracoronary administration f acetylcholine was previously 
validated (17-23). Acetylcholine produces endothelium- 
dependent relaxation in normal arteries by stimulating the 
release of endothelium-derived r laxing factor-nitric oxide 
(EDRF-NO), whereas endothelial dysfunction is associated 
with paradoxic vasoconstriction i response to acetylcholine 
(1%24). Because atherosclerosis may be present even when 
the coronary arteries are "normal" on angiography (25-28), 
angiographically normal arteries with impaired endothelial 
function may elicit the attenuation i  endothelium-dependent 
vasodilation obtained by intracoronary acetylcholine injection. 
Previous studies (18-23) have shown that the prevalence of 
well recognized coronary risk factors is associated with the 
attenuation of endothelium-dependent vasodilation in human 
coronary arteries even when these arteries are angiographically 
normal. To our knowledge, the influence of plasma Lp(a) 
(considered tobe an independent risk factor for atherosclero- 
sis) on human coronary endothelial vasomotor function has 
not been reported. The purpose of the present study was to test 
the hypothesis that elevated plasma Lp(a) levels impair coro- 
nary endothelial function before the formation of angiographi- 
cally recognizable atherosclerotic lesions by assessing coronary 
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vasomotor response to the endothelium-dependent vasodilator 
acetylcholine. 
Methods 
Study patients. Thirty patients who had been referred for 
cardiac atheterization to exclude coronary artery disease were 
recruited for the study. All patients had angiographically 
normal coronary arteries; that is, they had no angiographic 
stenoses or lumen irregularities in any segment of either the 
left anterior descending or right coronary artery. Patients with 
an obvious history of variant angina and previous myocardial 
infarction were excluded from the study. All patients had chest 
pain that was atypical for myocardial ischemia and had a 
negative or nondiagnostic response on an exercise tolerance 
test. All patients had normal eft ventricular function according 
to left ventriculography and normal cardiac output on right 
and left heart catheterization followed by coronary angiogra- 
phy. No patient had received any lipid-lowering drugs or diet 
therapies. History of hypertension (defined as history of ele- 
vated blood pressure >160/90 mm Hg requiring antihyperten- 
sive therapy) and habitual cigarette smoking were also docu- 
mented. Written informed consent for all procedures was 
obtained from each patient, and the Investigational Review 
Board of Tokyo Women's Medical College Hospital approved 
the study protocol. 
Study protocol. All drugs, including calcium channel and 
beta-adrenergic blocking agents, angiotensin-converting en-
zyme inhibitors and long-acting nitrates, were discontinued 
72 h before cardiac atheterization. After 100 U/kg of heparin 
had been given intravenously, right and left heart catheteriza- 
tion was performed. Vasomotor response to acetylcholine was 
studied according to a previously reported protocol (19). After 
right and left cardiac catheterization, a 5F bipolar cardiac 
pacing catheter was placed in the right ventricle, and the 
pacing rate was set at 40 beats/min as a backup in case of 
bradyarrhythmias. Control angiography of the right and left 
coronary arteries was performed using a 6F Judkins catheter by 
the standard percutaneous femoral approach using the Si- 
emens biplane cineangiography s stem. After a control coro- 
nary arteriogram was obtained, 50/~g of acetylcholine chloride 
(Daiichi Pharmaceutical Co., Tokyo, Japan) dissolved in 5 ml 
of warmed 0.9% saline solution was injected into the left 
anterior descending coronary artery at a rate of 0.25 ml/s 
through the Judkins catheter. After acetylcholine injection, left 
coronary arteriography was performed immediately. Finally, 
2.5 mg of isosorbide dinitrate (Eizai Pharmaceutical Co., 
Tokyo, Japan) was injected into the left anterior descending 
coronary, artery, and a coronal 3, arteriogram was again ob- 
tained. Coronary arteriograms were obtained with iopamidol, a
nonionized contrast medium (Iopamiron 370, Schering, Inc.). 
During all procedures, heart rate, arterial pressure and 12-lead 
electrocardiogram (ECG) were continuously monitored. 
Quantitative coronary angiography. Coronary lumen di- 
ameters were measured quantitatively using a cinevideodensi- 
tometric analysis system (model ID 8000 ImageData, NAC, 
Tokyo, Japan) as a previously validated technique (29,30). 
Because atherosclerosis is a segmental disease and vasomotor 
responses vary among segments (19), we chose three segments 
of the left anterior descending coronary artery from the control 
angiogram (proximal, middle and distal) in each patient for 
analysis. Each segment was defined with two anatomic features 
to reproducibly measure the same segment after each injec- 
tion. To avoid the possible influence of shear stress on 
vasomotion (20,31), we selected relatively straight segments 
that were away from the side branches. The lumen diameter 
was measured at end-diastole with optimal opacification of the 
coronary artery. Each segment studied was selected from 
biplane views, and the single-frame cine image was digitized 
(20 to 40/xm/pixel). By use of an edge-detection algorithm, a 
series of measurements of diameter along the length of each 
arterial segment (7 to 10 ram) were derived for each pixel line, 
and the mean diameter over the segment was calculated for 
each injection, as previously described (20). Calibration was 
achieved by measuring a magnification factor based on the 
known size of the angiographic atheter. Angiograms were 
analyzed by an operator who had no knowledge of the injection 
sequence. Percent diameter change was defined as follows: 
% diameter change 
Diameter (Ach or ISDN) - Diameter (control) 
Diameter (control) x 100, 
where Ach = acetylcholine; ISDN = isosorbide dinitrate. 
Measurements of Lp(a) and other lipid levels. Plasma 
Lp(a) levels were determined using a commercially available 
enzyme-linked immunosorbent assay kit (TintElize Lp(a) kit, 
Biopool AB, UmeL Sweden) in which polyclonal antibodies 
against purified apolipoprotein(a) re used. This method has 
been shown to be reproducible and appropriate for routine 
clinical application (32). In addition to Lp(a) levels, other 
plasma lipid levels in fresh plasma samples were determined 
after immediate centrifugation of whole blood. Total choles- 
terol, triglyceride and high density lipoprotein (HDL) choles- 
terol levels were measured using an enzymatic technique 
according to the specifications of the Lipid Research Clinics 
Program (33). Low density lipoprotein cholesterol was calcu- 
lated by the formula of Friedwald et al. (34). 
Statistical analysis. Hemodynamic changes after acetyl- 
choline and isosorbide dinitrate were compared by repeated- 
measures analysis of variance. Vasomotor esponse was ex- 
pressed as percent change in diameter. Univariate linear 
regression analysis was applied to evaluate the effect of Lp(a) 
and other variables on coronary vasomotion; for categoric 
variables (history of hypertension and smoking), one-way 
analysis of variance was performed. Multiple stepwise regres- 
sion analysis was then conducted to determine which of the 
univariate variables were significantly independent predictors 
of vasomotor response to acetylcholine. The variable with the 
highest partial correlation coefficient was entered at each 
step until no variable remained with an F value ->2. The 
differences between the high and low Lp(a) groups were 
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Table 1. Demographic Data for 30 Study Patients 
Vasomotor Response (% change from baseline) 
Achetylcholine Isosorbide Dinitrate 
Pt No./ Age TC TG LDLC HDLC Lp(a) 
Gender (yr) (mg/dl) (mgjdl )  /mg/dl)  (mg/dl)  (mgJdl) HT Smoker Prox Mid Dist Prox Mid Dist 
1/M 48 169 48 07 62 2 + - -8 --4 5 +22 +38 +37 
2/F 47 216 175 148 52 4 - + -20 + t7 +7 +36 +50 +25 
3/F 53 195 69 129 52 5 - - 26 -15 -6 +10 +11 +30 
4/M 59 189 115 122 44 6 + - 19 -7 -5 +10 +10 +3 
5/M 56 178 112 1(t3 53 10 - + 41 -38 -17 +75 +14 +12 
6/M 61 160 62 96 52 12 + + 19 -30 -30 +40 +61 +50 
7/M 59 126 153 64 63 13 + 0 +23 20 +30 +77 +18 
8/M 60 155 41 70 78 13 + -3 -24 -20 +70 +31 +67 
9/M 52 154 90 78 58 17 + 13 -2(1 -18 +10 +6 +25 
10/M 40 153 113 84 46 19 + - -11 18 -17 +25 +29 +20 
ll/M 57 164 61 102 50 22 - 39 -28 -31 +31 +24 +74 
12/M 65 242 97 161 62 22 - -26 -33 -27 +5 +7 +24 
13/F 60 195 116 122 50 22 + + -25 -33 -26 +27 +20 +14 
14/M 57 210 124 155 30 24 - -19 22 +9 +73 +89 +5 
15/F 50 191 44 113 69 24 + + -45 -31 -33 +17 +14 +5 
16/M 64 195 119 121 50 25 - + -31 -35 -20 +44 +59 +66 
17/M 64 152 71 77 63 25 + + +3 -35 -38 +64 +86 +18 
18/M 64 164 83 112 35 25 - + -15 -20 -38 +22 +9 +16 
I9/F 57 239 57 152 75 26 -42 -31 -33 +7 +27 +31 
20/M 65 18{I 111 113 45 29 -24 -20 22 +82 +47 +36 
21/M 57 187 162 115 40 30 - - -40 39 -9 +18 +22 +27 
22/M 61 176 291 83 35 31 + -15 -30 -29 +18 +50 +46 
23/M 69 267 244 183 35 32 - + -42 -33 -39 +25 +47 +53 
24/M 43 154 e,8 96 44 33 - + 41 -19 -21 +17 +31 +6 
25/F 54 226 139 153 45 36 + 35 -35 -43 +36 +36 +23 
26/M 63 243 88 169 56 40 + - 20 -28 -10 +45 +29 +12 
27/M 65 201 148 109 62 44 - + -47 -31 +13 +38 +23 +87 
28/M 37 148 46 74 65 52 - - -26 -33 -44 +26 +42 +45 
29/F 75 141 ~8 7~ 34 52 + + -44 -53 -45 +33 +45 +26 
30/M 69 174 113 92 59 72 + + -42 -40 -56 +33 +35 +20 
F = female; HDLC = high density lipoprotein cholesterol; HT = history of hypertension; LDLC = low density lipoprotein cholesterol; Lp(a) = lipoprotein(a); 
M = male; Prox (Mid, Dist) : proximal (middle. distal) segment of left anterior descending coronary artery; Pt = patient; TC total cholesterol; TG = triglycerides; 
+ =yes ; - -no .  
compared using the unpaired t test for continuous variables 
and the chi-square test for categoric variables (gender, history 
of hypertension and smoking). Vasomotion data are reported 
as mean value ± SEM. All other values are expressed as mean 
value +_ SD. Differences were considered statistically signifi- 
cant for p < 0.05. All statistical analysis was conducted using 
the STATVIEW 4.0 statistical package (Abacus Concepts, 
Inc.). 
Results 
Patient characteristics. The mean age of the patients 
studied was 58 _+ 9 years (range 37 to 75; 23 men, 7 women) 
(Table 1). Forty percent had a history of hypertension, and 
53% were smokers. None of the study patients had a history of 
diabetes, and glucose tolerance tested before catheterization 
was normal in all of them. The mean total, LDL and HDL 
cholesterol levels were 185 ± 34, 112 _+ 32 and 52 _+ 12 mg/dl, 
respectively. The mean Lp(a) level was 26 _+ 16 mg/dl (range 2 
to 72). 
Effect of acetylcholine and isosorbide dinitrate on systemic 
hemodynamic variables. Acetylcholine injection produced no 
change in heart rate (68 _+ 10 beats/rain before vs. 65 __ 10 
beats/rain after acetylcholine) and systolic blood pressure 
(134 _+ 15 mm Hg before vs. 133 _+ 14 mm Hg after 
acetylcholine). There were no chest pain symptoms or ECG 
changes after acetylcholine injection. After 2.5 mg of isosor- 
bide dinitrate was injected into the left anterior descending 
coronary, artery, systolic blood pressure decreased slightly (138 
± 12 mm Hg before vs. 133 ± 14 mm Hg after isosorbide 
dinitrate, p = 0.14), but heart rate was unchanged (66 _+ 12 
beats/rain before vs. 65 ± 10 beats/rain after isosorbide dini- 
trate). 
Coronary vasomotion. Coronary vasomotor response to 
acetylcholine (Fig. 1) ranged from +13% to -47% in the 
proximal, from +23% to -53% in the middle and from +13% 
to -56% in the distal segment of the left anter ior descending 
coronary artery. Correlat ion between variables and vasomotor 
response was analyzed in these three segments of the left 
anterior descending coronary artery. 
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According to univariate linear regression analysis, vasomo- 
tor response to acetylcholine was significantly correlated with 
Lp(a) (r = 0.47, p < 0.01 in the proximal; r = -0.61, p < 0.001 
in the middle; and r = 0.52, p < 0.01 in the distal segments of 
the left anterior descending coronary artery) (Fig. 2), with total 
and LDL cholesterol (r --- 0.39, p < 0.05; r = -0.37, p < 0.05 
in the proximal segment, respectively) and age (r = -0.40, p < 
0.05 in the middle segment). History of hypertension had a 
weak negative correlation with vasomotor response to acetyl- 
choline in the distal segment, but it was not statistically 
significant (r = -0.27, p = 0.15) (Table 2). 
Stepwise multiple regression analysis revealed a significant 
inverse correlation between Lp(a) and vasomotor response 
to acetylcholine in all segments of the left anterior descend- 
ing coronary artery tested (p < 0.01). Other than Lp(a), 
LDL cholesterol in the proximal segment, and age in the 
middle segment independently predicted attenuation of the 
endothelium-dependent vasodilator effect of acetylcholine 
(Table 3). 
All segments tested dilated in response to intracoronary 
isosorbide dinitrate (2.5 mg) (range +3% to +89%). There 
were no intersegment differences in mean vasomotor e- 
sponses to isosorbide dinitrate (proximal 33 -+ 4%, middle 
36 + 4% and distal 31 + 4% [left anterior descending coronary 
artery]). In addition, there was no correlation between vaso- 
motor response to isosorbide dinitrate and Lp(a) levels or 
other variables. 
Vasomotor responses inthe low (<25 mg/dl) and high (->25 
mg/dl) Lp(a) groups were compared. Most previous tudies 
(3-10) reported that the atherogenic threshold of plasma 
Lp(a) is 20 to 30 mg/dl. There were no differences between the 
two study groups for variables other than Lp(a) level (Table 4). 
Vasomotion in response to acetylcholine was significantly 
more constrictive in the high than the low Lp(a) group for each 
Figure 1. Angiograms ofthe left anterior descending coronary artery. 
A, Baseline. B, Acetylcholine infusion. C, Isosorbide dinitrate infusion. 
segment studied (proximal -19 + 4% vs. -31 _+ 4%, p < 0.05; 
middle -17 _+ 5% vs. -32 _+ 2%, p < 0.01; distal -15 + 3% 
vs. -29 _+ 6%, p < 0.05 [left anterior descending coronary 
artery]). Vasomotor esponse to isosorbide dinitrate was 
slightly greater in the high than the low Lp(a) group for all 
segments tested, but differences were not statistically signifi- 
cant (proximal 32 _+ 6% vs. 34 _+ 5%, p = 0.82; middle 32 +_ 
7% vs. 39 _+ 5%, p = 0.40; distal 27 _+ 6% vs. 34 _+ 6%, p = 
0.40 [left anterior descending coronary artery]) (Fig. 3). 
Discuss ion  
The results of the present study demonstrate hat in pa- 
tients with angiographically normal coronary arteries, plasma 
Lp(a) levels are independently associated with coronary vaso- 
motor responses to acetylcholine but not isosorbide dinitrate. 
Attenuation of the endothelium-dependent vasodilator effect 
and preservation of the endothelium-independent vasodilator 
effect suggest hat elevated plasma levels of Lp(a) disturb 
endothelium-mediated vasomotor function. To our knowledge, 
this is the first study to demonstrate he independent effect of 
Lp(a) on human coronary endothelial vasomotor function in 
vivo. 
Vasomotor response of coronary artery. Increasing evi- 
dence has shown that the vascular endothelium plays an 
important role in regulating vasotone by releasing endothelium- 
derived relaxing factor (EDRF) (24) or endothelium-derived 
contracting factor (EDCF) (35) in response to various physi- 
cochemical nd hormonal stimuli. To assess coronary endothe- 
lial function in vivo, analysis of vasomotion in response to 
intracorona~, acetylcholine was previously validated (17-23). 
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Figure 2. Coronary vasomotor response to intracoronary 
acetylcholine (ACH) (50 jzg) as a function of lipopro- 
rein(a) [Lp(a)] plasma level in the proximal (top), middle 
(middle) and distal (bottom) left anterior descending 
coronary artery. The percent diameter change in response 
to acetylcholine (vertical axis) has a significant inverse 
correlation. 
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Acetytcholine produces endothelium-dependent r laxation in 
normal arteries of most mammalian species by stimulating 
release of EDRF-NO (24). However, acetylcholine licits 
vasoconstriction when it acts directly on the vascular smooth 
muscle without the endothelium-mediated vasodilator effect 
(16,24). In the present study, most of the coronary artery 
segments tested constricted in response to acetylcholine even 
though they were angiographically entirely normal. We used a 
single infusion rate of 50 t~g of acetylcholine, which was an 
estimated 10 -5 mol/liter in the left anterior descending coro- 
nary artery. The concentration of acetylcholine in our study 
was relatively high compared with that in previous tudies (17) 
that reported vasodilation of angiographically normal coronary 
arteries in response to 10 9 to 10 6 mol/liter of acetylcholine. 
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Table 2. Univariate Correlation of Vasomotor Response of Left Anterior Descending Coronary Artery 
to Acetylcholine 
Proximal Middle Distal 
r p r p r p 
Coeff Value Coeff Value Coeff Value 
Age -0.17 (I.37 -0.40 <0.05 0.24 0.21 
TC 0.39 < 0.05 0.16 0.41 0.16 0.39 
LDLC -0.37 <0.05 -0.06 0.75 0.21 0.28 
HDLC 0.16 0.40 0.13 (I.50 -0.05 0.82 
TG -0.06 0.76 0,08 0.68 0,13 0.49 
HT 0.09 0.65 (I. 14 (I.45 -0.27 0.15 
Smoking 0.06 0.74 - i!.06 (I.74 0.10 0.59 
Lp(a) 0.47 <0.01 (I.61 <(I.001 -0.52 <0.01 
Coeff = coefficient: other abbreviations a in Table I. 
Thus, the direct constrictive ffect of acetylcholine on vascular 
smooth muscle may overcome the endothelium-mediated va- 
sodilator effect at the relatively higher concentration. I  addi- 
tion, the constrictive response to acetylcholine might be asso- 
ciated in part with the older age of our patients (mean age 
58 -+ 9 years). Similarly, Yasue et al. (19) reported that 
intracoronary infusion of 10 -5 mol/liter acetylcholine caused 
constriction of angiographically normal coronary arteries in 
most of their older subjects (>30 years), whereas it elicited 
vasodilation among younger subjects. The net response to 
acetylcholine depends on the interplay between direct vaso- 
constriction and EDRF-mediated vasodilation and may vary in 
association with the dose of acetylcholine. However, previous 
studies (18-23) have shown that several doses (at least 10 -7 to 
10 -4 mol/liter) of acetylcholine can detect endothelial dysfunc- 
tion. 
In the present study, all arterial segments tested had 
preserved endothelium-independent vasodilation in response 
to isosorbide dinitrate (an exogenous mimic of EDRF-NO), 
and most had attenuated ndothelium-dependent vasodilation. 
This dissociation of vasomotion i  response to acetylcholine 
and isosorbide dinitrate suggests the possibility of previous 
endothelial damage ven though medial smooth muscle is 
functionally intact. In addition, we believe that the endothelial 
dysfunction shown in the present study did not result from the 
inability of smooth muscle to respond to EDRF-NO but 
reflected impaired production or release of the mediator f om 
endothelial cells. The same observations regarding human 
coronary vasomotor response to acetylcholine and nitrocom- 
pounds were reported previously (17-23). 
Previous histopathologic studies have shown that the prox- 
imal segment of the left anterior descending coronary artery is 
particularly vulnerable to atherosclerosis. Indeed, it has been 
shown (19) that even in angiographically normal subjects, 
constriction in response to acetylcholine was greater in the 
proximal than the distal segment of the left anterior descend- 
ing coronary artery. However, in the present study there was 
no difference in vasomotor response to acetylcholine among 
the segments, indicating that topical and geometric nfluences 
were small in our study patients. The basis of the discrepancy 
between our results and those of the previous tudy is unclear, 
but the fact that we avoided branching points and bending 
portions for analysis might contribute to our observations. 
Lp(a) and endothelial dysfunction. Endothelial injury is 
thought to be an important initiating factor in the pathogenesis 
of atherosclerosis (11). It has been shown in humans that well 
recognized coronary risk factors, such as hypercholesterolemia 
(18), hypertension (21), family history of coronary heart dis- 
ease (18) and aging (18,19), are associated with attenuation f
endothelium-dependent vasodilation of angiographically nor- 
mal coronary arteries. Our results are consistent with these 
previous reports that abnormal vasomotor response to acetyl- 
choline correlates with total or LDL cholesterol level and with 
age in patients without lumenal irregularities or stenoses on 
coronary angiography. The present study also shows that 
attenuation of endothelium-dependent vasodilation is inde- 
Table 3. Multivariate Analysis of Vasomotor Response of Left Anterior Descending Coronary Artery to Acetylcholine 
Proximal Middle Distal 
Coefficient F Coefficient F Coefficient F 
(standardized) SE Value* (standardized) SE Value* (standardized) SE Value* 
Lp(a) -0.50 (-0.49) 0.16 10.2"i 0.56 (0.54)  0.16 12.35 -0.56 (-0.52) 0.17 10.6t 
LDLC -0.20 (-1i.39) 0.08 6.6:]: - -  - -  0.1 - -  - -  1.3 
Age - -  - -  0.1 -41.43 (-4).23) 0.29 2.2 - -  - -  0.2 
Intercept t).6 14.4 - 8.1 
Adjusted R 2 1i.33 0.42 0.25 
*F value to enter equation ~2. tp < 0.01. -p ,  I).(15.-- not cntered into equation, Abbreviations as in Table 1. 
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Table 4. Comparison ofPlasma Levels of Lipids and Clinical Data 
in the Low and High Lipoprotein(a) Groups 
Low Lp(a) Group High Lp(a} Group 
[Lp(a) < 25 mgjdl] [Lp(a) -> 25 mg/dl] p 
(n = 151 (n = 15) Value 
Age (yr) 55 + 7 60 ± 10 0.08 
Male gender 8(I ~vc 73~; 0.67 
TC (mg/dl) 180 + 30 19(I + 38 0.43 
LDLC (mg/dl) 110 ± 30 115 ± 35 0.65 
TG (mg/dl) 95 +_ 40 12(/± 69 (/.22 
HDLC (mg/dl) 55 + 11 5(1 + 13 0.25 
HT 40% 40q~ 0.70 
Smoking 53c+ (~)q~ 0.46 
Lp(a) (mg,'dl) 14 + S 37 + 13 <0.001 
Data presented are mean + SD or percent ofpatients. Abbreviations as in 
Table 1. 
pendently associated with plasma Lp(a) levels as well as the 
previously reported predictors. 
There are two possible interpretations of the significant 
relation between plasma Lp(a) levels and attenuation of 
endothelium-dependent vasodilation. 
1. Coronary angiography is not sensitive nough to detect 
early atherosclerotic changes that already exist. There has been 
increasing evidence that even angiographically normal arteries 
show early atherosclerotic changes on histologic examination 
(25,26) or intravascular ultrasound imaging (27,28). It is there- 
fore likely that some atherosclerosis may exist in association 
with a high Lp(a) level even in subjects with angiographically 
normal coronary arteries. Numerous reports (17-21) have 
demonstrated that dysfunction i  the release of EDRF-NO 
from endothelial cells appears to occur at all stages of the 
atherosclerotic process. Alternatively, ultrastructural endothe- 
lial damage, or partial endothelial denudation, could explain 
our present observation. These undetectable changes in endo- 
thelial layer might result in enhancement of endothelial per- 
meability, which would allow direct access of acetylcholine to
the vascular muscle cells. We therefore cannot rule out the 
possibility that endothelial vasomotor dysfunction may result 
from early atherosclerotic changes associated with high plasma 
levels of Lp(a) that are undetectable bycoronary angiography. 
2. Lipoprotein(a) itself may inhibit the endothelium- 
dependent vasodilator effect without structural changes in the 
arterial wall. Reddy et al. recently reported that patients with 
normal angiographic results and no measurable disease by 
intracoronary ultrasound could exhibit selective ndothelial 
dysfunction i association with coronary risk factors. Galle et 
al. (36) showed that even a brief incubation with LDL choles- 
terol inhibits the vasodilator esponse of rabbit aorta to 
acetylcholine, suggesting that endothelial dysfunction can oc- 
cur without morphologic hanges. Whether Lp(a) itself di- 
rectly disturbs endothelium-dependent vasodilation is un- 
known, but we cannot exclude the possibility that Lp(a) itself 
adversely affects the endothelium-dependent vasodilator effect in 
response to acetylcholine. Lipoprotein-induced ndothelial dys- 
function has been extensively studied in response to LDL (36,37). 
Endothelial cells can modify native LDL to the oxidized form, 
which is more atherogenic than the native one. In vitro studies 
(37) have demonstrated the inhibitory influence of oxidized LDL 
on the release of EDRF-NO by disrupting endothelial recep- 
tor transduction. This inhibitory effect of oxidized LDL on 
endothelium-dependent r laxation is associated with the lipid 
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Figure 3. Difference in effects of 
intracoronary acetylcholine (ACH 
[bottom]) and isosorbide dinitrate 
(ISDN [top]) on coronary vasomo- 
tor response between low (<25 
mg/dl [open bars]) and high (->25 
mg/dl [solid bars]) lipoprotein(a) 
[Lp(a)] groups. Data shown are 
mean value (columns) -+ SE (error 
bars). *p < 0.05 versus low Lp(a) 
group, tp < 0.01 versus low Lp(a) 
group. LAD = left anterior de- 
scending coronary artery. 
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fraction of the molecule (37). It has been shown (38) that 
Lp(a) is also modified to an oxidized form. Because the lipid 
configurations between LDL and Lp(a) by which LDL is linked 
to apolipoprotein(a) re similar, the possibility that Lp(a) [or 
oxidized Lp(a)] may directly inhibit release of EDRF-NO 
cannot be ruled out. 
There has been increasing evidence that Lp(a) is an inde- 
pendent risk factor for atherosclerosis (3-10). However, the 
precise pathophysiologic mechanisms by which Lp(a) contrib- 
utes to the development of atherosclerosis are still unclear. 
Interference of Lp(a) with fibrinolytic activity, because of the 
high homology of apolipoprotein(a) with plasminogen, has 
been suspected to be associated with its atherogenicity (39,40). 
This may in part account for the thrombogenicity of Lp(a) but 
not for all its atherogenicity as a cardiovascular pathogen. 
Recent immunopathologic studies (41,42) have shown that 
vessel wall apolipoprotein(a) concentration and plasma Lp(a) 
concentration have a significant correlation. More recently, 
Lawn et al. (43) reported that transgenic mice expressing 
human apolipoprotein(a) were susceptible to the development 
of lipid-staining lesions and that apolipoprotein(a) colocalizes 
with lipid deposition in the arterial wall. According to these 
previous tudies, it is likely that elevated plasma levels of Lp(a) 
cause its deposition in the arterial intima as do elevated levels 
of LDL. Although both Lp(a) and LDL are atherogenic 
lipoproteins tructurally resembling each other, the effect of 
Lp(a) on endothelial vasomotor function has not yet been 
studied. Our results suggest hat elevated plasma levels of 
Lp(a) were associated with inadequate production/release of 
EDRF-NO, although it is undetermined whether the effect of 
Lp(a) on endothelium-dependent vasomotor esponse is a 
direct inhibitory effect of Lp(a) or the result of undetectable 
atherosclerosis a sociated with Lp(a) deposition in the arterial 
wall. 
Correlation between Lp(a) and other variables. There was 
no significant relation between Lp(a) and other lipids, age or 
prevalence of hypertension or smoking in our study patients 
(data not shown). Our data are consistent with recent data 
from the Framingham Offspring Study (44) that showed that 
plasma Lp(a) levels were not correlated with well recognized 
risk or antirisk factors. One exception was the inverse relation 
between plasma levels of Up(a) and triglycerides, even though 
it accounted for only -0.5% of the variation in Lp(a) levels. 
Numerous reports (3-10) have shown that Lp(a) indepen- 
dently relates to atherosclerotic disease over other lipids and 
lipoproteins. 
Study limitations. The present study included only Japa- 
nese subjects, and our results do not necessarily apply to other 
racial groups. It is known that mean plasma levels of Lp(a) and 
its distribution vary among racial groups (45,46). The racial 
variation of Lp(a) distribution isassociated with differences in
phenotype xpression among racial groups (46). Nevertheless, 
previous data have shown that the mean levels and distribution 
of Lp(a) in the Japanese are similar to those in whites (47), and 
a high plasma Lp(a) level has also been reported (7,8) to be 
significantly associated with atherosclerotic disease in the 
Japanese. 
Conclusions. Although the pathogenesis ofatherosclerosis 
is multifactorial, lipoprotein-induced endothelial injury/ 
dysfunction may play an important role in the development of
atherosclerosis. In the present study, we showed that elevated 
Lp(a) was associated with an impaired vasodilator effect of 
acetylcholine even when atherosclerotic lesions were not rec- 
ognizable by angiography. These results uggest that elevated 
Lp(a) causes endothelial dysfunction, and this may in part 
contribute to the development of subsequent a herosclerosis, 
as shown in epidemiologic studies. 
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